Preparation and evaluation of sinomenine hydrochloride in situ gel for uveitis treatment

International Immunopharmacology

Volumn 17, Issue 1, 2013, Pages 99-107

  Song, Jike ^a   Bi, Hongsheng ^a   Xie, Xiaofeng ^a   Guo, Junguo ^a   Wang, Xingrong ^a   Liu, Damei ^a  

^a SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Experimental autoimmune anterior uveitis; In situ gel; Preparation and evaluation; Sinomenine hydrochloride

Indexed keywords

CARBOPOL 940; HYDROXYPROPYLMETHYLCELLULOSE; SINOMENINE; SINOMENINE HYDROCHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS HUMOR; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DRUG ELIMINATION; DRUG FORMULATION; EXPERIMENTAL AUTOIMMUNE ANTERIOR UVEITIS; EYE IRRITATION; FEMALE; GEL; IN SITU GEL; IRIDOCYCLITIS; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE; VISCOSITY;

EID: 84879236596     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.05.020     Document Type: Article

References (43)

1. Han G, Shao H, Peng Y, Zhang P, Ke Y, Kaplan HJ, et al. Suppressor role of rat CD8+CD45RClow T cells in experimental autoimmune uveitis (EAU). J Neuroimmunol 2007;183:81-8. (Pubitemid 46204912)
2. Vistica BP, Shi G, Nugent L, Tan C, Altman A, Gery I. SLAT/Def6 plays a critical role in the pathogenic process of experimental autoimmune uveitis (EAU). Mol Vis 2012;18:1858-64.
3. Yadav UC, Shoeb M, Srivastava SK, Ramana KV. Aldose reductase deficiency protects from autoimmune- and endotoxin-induced uveitis in mice. Invest Ophthalmol Vis Sci 2011;52:8076-85.
4. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol 2005;140:509-16. (Pubitemid 41224845)
5. Sen HN, Drye LT, Goldstein DA, Larson TA, Merrill PT, Pavan PR, et al. Hypotony in patients with uveitis: the Multicenter Uveitis Steroid Treatment (MUST) trial. Ocul Immunol Inflamm 2012;20:104-12.
6. Sangwan VS. Treatment of uveitis: beyond steroids. Indian J Ophthalmol 2010;58: 1-2.
7. Sonmez K, Ozturk F. Complications of intravitreal triamcinolone acetonide for macular edema and predictive factors for intraocular pressure elevation. Int J Ophthalmol 2012;5:719-25.
8. Mathews D, Mathews J, Jones NP. Low-dose cyclosporine treatment for sight-threatening uveitis: efficacy, toxicity, and tolerance. Indian J Ophthalmol 2010;58:55-8.
9. Manickam B, Jha P, Hepburn NJ, Morgan BP, Harris CL, Bora PS, et al. Suppression of complement activation by recombinant Crry inhibits experimental autoimmune anterior uveitis (EAAU). Mol Immunol 2010;48:231-9.
10. Bodaghi B, Rao N. Relevance of animal models to human uveitis. Ophthalmic Res 2008;40:200-2. (Pubitemid 351562903)
11. Caspi RR. A look at autoimmunity and inflammation in the eye. J Clin Invest 2010;120:3073-83.
12. Teng P, Liu HL, Deng ZS, Shi ZB, He YM, Feng LL, et al. Synthesis and biological evaluation of unique stereodimers of sinomenine analogues as potential inhibitors of NO production. Bioorg Med Chem 2011;19:3096-104.
13. Qian L, Xu Z, Zhang W, Wilson B, Hong JS, Flood PM. Sinomenine, a natural dextrorotatory morphinan analog, is anti-inflammatory and neuroprotective through inhibition of microglial NADPH oxidase. J Neuroinflammation 2007;4:23.
14. Wang Q, Li XK. Immunosuppressive and anti-inflammatory activities of sinomenine. Int Immunopharmacol 2011;11:373-6.
15. Teng P, Liu HL, Zhang L, Feng LL, Huai Y, Deng ZS, et al. Synthesis and biological evaluation of novel sinomenine derivatives as anti-inflammatory agents. Eur J Med Chem 2012;50:63-74.
16. Chen DP, Wong CK, Leung PC, Fung KP, Lau CB, Lau CP, et al. Anti-inflammatory activities of Chinese herbal medicine sinomenine and Liang Miao San on tumor necrosis factor-α-activated human fibroblast-like synoviocytes in rheumatoid arthritis. J Ethnopharmacol 2011;137:457-68.
17. Li X, Li X, Zhou Y, Liu Y, Guo M, Zhu Q, et al. Development of patch and spray formulations for enhancing topical delivery of sinomenine hydrochloride. J Pharmacol Sci 2010;99:1790-9.
18. Wang Y, Ma D, Jie Y, Wu Y, Pan Z. Sinomenine can prolong high-risk corneal graft survival in a rat model. Immunotherapy 2012;4:581-6.
19. Cheng Y, Zhang J, HouW, Wang D, Li F, Zhang Y, et al. Immunoregulatory effects of sinomenine on the T-bet/GATA-3 ratio and Th1/Th2 cytokine balance in the treatment of mesangial proliferative nephritis. Int Immunopharmacol 2009;9:894-9.
20. Wang Q, Li XK. Immunosuppressive and anti-inflammatory activities of sinomenine. Int Immunopharmacol 2011;11:373-6.
21. Ye MR, Liu L, Zeng YE, Zhang LQ, Tan YH, Deng SJ, et al. Studies on the relationship between sinomenine distribution and its organic toxicology. Chin Pharmacol Bull 2001;17:65-9. (Pubitemid 32410560)
22. Xu M, Liu L, Qi C, Deng B, Cai X. Sinomenine versus NSAIDs for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Planta Med 2008;74:1423-9.
23. Nanjawade BK, Manvi FV, Manjappa AS. In situ-forming hydrogels for sustained ophthalmic drug delivery. J Control Release 2007;122:119-34. (Pubitemid 47361409)
24. Wu H, Liu Z, Peng J, Li L, Li N, Li J, et al. Design and evaluation of baicalin-containing in situ pH-triggered gelling system for sustained ophthalmic drug delivery. Int J Pharm 2011;410:31-40.
25. Pandey A. Development and optimization of levobunolol hydrochloride in-situ gel for glaucoma treatment. Int J Pharm Biol Arch 2010;1:134-9.
26. Manjappa AS, Nanjwade BK, Manvi FV, Murthy RR. Sustained ophthalmic in situ gel of ketorolac tromethamine: rheology and in vivo studies. Drug Dev Res 2009;70: 417-24.
27. Başaran B, Bozkir A. Thermosensitive and pH induced in situ ophthalmic gelling system for ciprofloxacin hydrochloride: hydroxypropyl-beta- cyclodextrin complex. Acta Pol Pharm 2012;69:1137-47.
28. Gratieri T, Gelfuso GM, Rocha EM, Sarmento VH, de Freitas O, Lopez RF. A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. Eur J Pharm Biopharm 2010;75:186-93.
29. Gupta S, Samanta MK, Raichur AM. Dual-drug delivery system based on in situ gel-forming nanosuspension of forskolin to enhance antiglaucoma efficacy. AAPS Pharm Sci Tech 2010;11:322-35.
30. Gupta S, Vyas SP. Carbopol/chitosan based pH triggered in situ gelling system for ocular delivery of timolol maleate. Sci Pharm 2010;78:959-76.
31. Gratieri T, Gelfuso GM, Rocha EM, Sarmento VH, de Freitas O, Lopez RF. A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. Eur J Pharm Biopharm 2010;75:186-93.
32. Carnali JO, Naser MS. The use of dilute solution viscosity to characterize the networkproperties of carbopol microgels. Colloid Polym Sci 1992;270:183-93.
33. Eaga CM, Jagan MK, Venkatesham A. Preparation and evaluation of in-situ-gels for ocular drug delivery. J Pharm Res 2009;2:1089-94.
34. Draize JH, Woodard G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther 1944;82:377-90.
35. Liu R, Liu Z, Zhang C, Zhang B. Nanostructured lipid carriers as novel ophthalmic delivery system for mangiferin: improving in vivo ocular bioavailability. J Pharm Sci 2012;101:3833-44.
36. Jha P, Manickam B, Matta B, Bora PS, Bora NS. Proteolytic cleavage of type I collagen generates an autoantigen in autoimmune uveitis. J Biol Chem 2009;284: 31401-11.
37. Jain SP, Shah SP, Rajadhyaksha NS, Singh PSPP, Amin PD. In situ ophthalmic gel of ciprofloxacin hydrochloride for once a day sustained delivery. Drug Dev Ind Pharm 2008;34:445-52. (Pubitemid 351519671)
38. Stahl M, Bouw R, Jackson A, Pay V. Human microdialysis. Curr Pharm Biotechnol 2002;3:165-78. (Pubitemid 34520932)
39. Roggeband R, York M, Pericoi M, Braun W. Eye irritation responses in rabbit and man after single applications of equal volumes of undiluted model liquid detergent products. Food Chem Toxicol 2000;38:727-34. (Pubitemid 30447467)
40. Plock N, Kloft C. Microdialysis-theoretical background and recent implementation in applied life-sciences. Eur J Pharm Sci 2005;25:1-24. (Pubitemid 40602191)
41. Gratieri T, Gelfuso GM, de Freitas O, Rocha EM, Lopez RF. Enhancing and sustaining the topical ocular delivery of fluconazole using chitosan solution and poloxamer/chitosan in situ forming gel. Eur J Pharm Biopharm 2011;79:320-7.
42. Katragadda S, Gunda S, Hariharan S, Mitra AK. Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections. Int J Pharm 2008;359:15-24.
43. Boddu SH, Gunda S, Earla R, Mitra AK. Ocular microdialysis: a continuous sampling technique to study pharmacokinetics and pharmacodynamics in the eye. Bioanalysis 2010;2:487-507.